Results 91 to 100 of about 741,060 (264)

A Hybrid Bioprinting–Microfabrication Approach to Controllable Multitype Spheroid Arrays for Modeling Tumor Heterogeneity

Advanced Healthcare Materials, EarlyView.
This work introduces a “cancer‐in‐a‐well” technology that recreates tumor heterogeneity in vitro using multitype spheroid arrays. Combining bioprinting/microdispensing with microstructured culture devices, the system improves drug screening and modeling of tumor complexity.
Simone Bonetti, Eva Clemente, Emanuela Mensà, Marco de Maria, Fulvia Farabegoli, Emanuela Saracino, Barbara Bortolani, Emanuela Marcelli, Renato Brandimarti, Dario de Biase, Giampaolo Zuccheri   +10 more
wiley   +1 more source

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Chinese Journal of Cancer, 2016
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment in ...
Jiang-Yong Yu, Si-Fan Yu, Shu-Hang Wang, Hua Bai, Jun Zhao, Tong-Tong An, Jian-Chun Duan, Jie Wang   +7 more
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Detection and Its Clinical Significance of EGFR Gene Mutation and Gene Amplification in 187 Patients with Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective It has been demonstrated that epidermal growth factor receptor (EGFR) signal pathway had an important role in the oncogenesis and development of non-small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs)
Qinghua ZHOU, Jun CHEN, Zuoqing SONG, Weiqiang WAN, Xiaoming QIU, Daxing ZHU, Sen WEI, Yuli WANG, Yongwen LI, Jing WANG, Gang CHEN, Ying LI, Hongyu LIU   +12 more
doaj  

An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.

PLoS ONE, 2016
An association between epidermal growth factor receptor (EGFR) and clinical characteristics of non-small cell lung cancer (NSCLC) was reported ten years ago. In addition, a different type of relationship was seen in different ethic races.
Wen-E Wei, Nai-Quan Mao, Shu-Fang Ning, Ji-Lin Li, Hai-Zhou Liu, Tong Xie, Jian-Hong Zhong, Yan Feng, Chang-Hong Wei, Li-Tu Zhang   +9 more
doaj   +1 more source

V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors [PDF]

, 2014
IntroductionWe previously demonstrated that a family predisposed to lung cancer harbored a V843I substitution in the epidermal growth factor receptor (EGFR) protein.
Nakamura, Hiroyuki, Tomonori Kishino, Hiroaki Ohnishi, Fujiwara, Masachika, Goto, Hajime, Masachika Fujiwara, Takashi Watanabe, Matsushima, Satsuki, Satsuki Matsushima, Takeshi Morii, Ohtsuka, Kouki, Hajime Goto, Morii, Takeshi, Kishino, Tomonori, Watanabe, Takashi, Kouki Ohtsuka, Ohnishi, Hiroaki, Hiroyuki Nakamura   +17 more
core   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, EarlyView.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma

, 2018
Wenting Jiang,1,* Han Wang,1,* Yongmei Cui,1,* Yiyan Lei,2 Yuefeng Wang,1 Di Xu,3 Neng Jiang,1 Yangshan Chen,1 Yu Sun,1 Yang Zhang,4 Jessica Cao,5 Zunfu Ke1 1Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou ...
Zhang Y, Cao J, Chen YS, Cui YM, Xu D, Jiang WT, Wang H, Wang YF, Jiang N, Sun Y, Ke ZF, Lei YY   +11 more
core  

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma [PDF]

, 2008
Tissue heterogeneity of EGFR gene mutation was studied in 10 formalin-fixed paraffin-embedded (FFPE) samples from four cases that demonstrated EGFR mutations in snap-frozen samples.
Lara-Guerra, Humberto, Tsao, Ming-Sound, Sakurada, Akira, Liu, Ni, Shepherd, Frances A.   +4 more
core   +1 more source

Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer

Advanced Science, EarlyView.
The mechanisms of SeNPs therapy in cancer treatment, encompass three parallel actions: (1) seleno‐amino acids, key metabolites, upregulate GPX2 expression, thereby inhibiting tumor metastasis via the GPX2‐HIF1α‐VEGF signaling pathway; (2) selenite (SeO32−), an inorganic metabolite, forms hydrogen bonds with amino acid residues 13–17 of the KRAS G13D ...
Xiaoting Liu, Chong Wu, Shiyao Song, Li Ma, Shaoqing Huang, Yuting He, Qinghai Li, Yanzhou Chang, Dan Jiang, Yong Mei, Junchao Cai, Zhenshuang Du, Tianfeng Chen, Weiling He   +13 more
wiley   +1 more source